Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6790841
2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
expired -
US 6790615
Methods and compositions for regulating cell cycle progression
expired -
US 6790629
Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
expired -
US 6787571
Anti-inflammatory compounds derived from Pseudopterorgorgia elisabethae
expired -
US 6787321
Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
expired -
US 6787090
Method of producing structures using centrifugal forces
expired -
US 6787365
Inhibition of L-selectin and P-selectin mediated binding using heparin
expired -
US 6787519
Methods of treating disorders related to apoE
expired -
US 6783760
Combined cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
expired -
US 6783936
Antigenic epitopes with Lym-1 reactivity and uses thereof
expired -
US 6780837
Prevention of retinal injury and degeneration by specific factors
expired -
US 6780406
Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
expired -
US 6780414
METHODS OF IDENTIFYING BACTERIAL GENES THAT ARE INCOMPATIBLE WITH BACTERIAL PATHOGENICITY, AND THE USE OF SUCH GENES, SUCH AS CADA, TO REDUCE PATHOGENICITY IN A BACTERIA OR TO COMBAT PATHOGENIC BACTERIAL INFECTIONS
expired -
US 6777578
Hydroxyphenstatin and the prodrugs thereof
expired -
US 6777200
Kinesin motor modulators derived from the marine sponge Adocia
expired -
US 6777192
Recombinant neospora antigens and their uses
expired -
US 6777234
Mammalian muscle construct and method for producing same
expired -
US 6777231
Adipose-derived stem cells and lattices
expired -
US 6774219
Candida albicans gene, integrin-like protein, antibodies, and methods of use
expired -
US 6774105
Methods of using latent TGF-&bgr; binding proteins
expired -
US 6774218
Mutants of streptococcal toxin C and methods of use
expired -
US 6774278
Coated implantable medical device
expired -
US 6773706
Identification of sortase gene
expired -
US 6770740
Crosslinked DNA condesate compositions and gene delivery methods
expired -
US 6770473
hKIS compositions and methods of use
expired -
US 6770273
Vaccine based on attenuated Haemophilus somnus
expired -
US 6770478
Erythrocytic cells and method for preserving cells
expired -
US 6770624
Treatment of heart failure with growth hormone
expired -
US 6768009
N-halamine vinyl compounds and their polymeric biocides
expired -
US 6767541
HER-2/neu overexpression abrogates growth inhibitory pathways
expired -
US 6764826
Inhibitors of C-reactive protein induced inflammation
expired -
US 6764681
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
expired -
US 6761894
Abundant extracellular products and methods for their production and use
expired -
US 6762286
Modified vitamin K-dependent polypeptides
expired -
US 6759048
Neutralization-sensitive epitopes of Cryptosporidium parvum
expired -
US 6759044
Cryptopain antibodies for prophylaxis, treatment, diagnosis and detection of Cryptosporidium species
expired -
US 6759385
Methods to treat undesirable immune responses
expired -
US 6758828
Catheter for cell delivery in tissue
expired -
US 6759530
IBD-associated microbial nucleic acid molecules
expired -
US 6756062
Preparation of drug particles using evaporation precipitation into aqueous solutions
expired -
US 6756036
Methods for treating cancer using PSCA antibodies and fragments thereof
expired -
US 6756055
Cationic lipid compositions targeting angiogenic endothelial cells
expired -
US 6756408
Methods and materials for protecting against myocardial cell damage related to coronary intervention by regional beta blocker therapy
expired -
US 6756210
Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
expired -
US 6752996
Use of parapox PP30 protein to modify immune responses to administered antigens
expired -
US 6752993
Abundant extracellular product vaccines and methods for their production and use
expired -
US 6752995
Nucleic acid and polypeptide sequences useful as adjuvants
expired -
US 6753411
Protection-of-telomere-1 (POT-1) proteins
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory